Literature DB >> 8099176

Future of oral iron chelator deferiprone. (L1) ICOC committee.

G J Kontoghiorghes, M B Agarwal, P Tondury, M J Kersten, M Jaeger, G Vreugdenhil, A Vania, Y E Rahman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8099176     DOI： 10.1016/0140-6736(93)90925-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 2.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Iron chelators as therapeutic agents against Pneumocystis carinii.

Authors:  G A Weinberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.